ERBB2 and breast carcinoma: Endocrine therapy has become the mainstay of treatment for hormone receptor positive, human epidermal grown factor receptor 2 negative (HR+HER2-) breast cancer patients and often represents the first among several lines of treatment in metastatic disease.